{
    "2018-08-23": [
        [
            {
                "time": "2018-01-02",
                "original_text": "Novartis Breast Cancer Drug Meets Primary Goal in Phase III",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Breast",
                        "Cancer",
                        "Drug",
                        "Phase",
                        "III",
                        "Primary",
                        "Goal"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals",
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-03",
                "original_text": "Update on Roche’s Oncology Drugs: Tarceva, Cotellic, and Erivedge",
                "features": {
                    "keywords": [
                        "Roche",
                        "Oncology",
                        "Drugs",
                        "Tarceva",
                        "Cotellic",
                        "Erivedge"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals",
                        "oncology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-04",
                "original_text": "Roche: Recent Developments and Analysts’ Ratings in August",
                "features": {
                    "keywords": [
                        "Roche",
                        "Developments",
                        "Analysts",
                        "Ratings",
                        "August"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-05",
                "original_text": "CYRX: Commercial Support and Clinical Trial Revenue Ramping. Commercial Support Pipeline Increasing Long-Term Value",
                "features": {
                    "keywords": [
                        "CYRX",
                        "Commercial",
                        "Support",
                        "Clinical",
                        "Trial",
                        "Revenue",
                        "Pipeline",
                        "Long-Term",
                        "Value"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotechnology",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-08",
                "original_text": "Large-Cap Pharma Rebounds: 2 Stocks to Boost Your Portfolio",
                "features": {
                    "keywords": [
                        "Large-Cap",
                        "Pharma",
                        "Rebounds",
                        "Stocks",
                        "Portfolio"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-09",
                "original_text": "The Daily Biotech Pulse: Novartis Breast Cancer Trial Meets Endpoint, Medpace's Offering, Dexcom Buys TypeZero",
                "features": {
                    "keywords": [
                        "Biotech",
                        "Pulse",
                        "Novartis",
                        "Breast",
                        "Cancer",
                        "Trial",
                        "Endpoint",
                        "Medpace",
                        "Dexcom",
                        "TypeZero"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "biotechnology",
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-10",
                "original_text": "The Swiss Stock Market Held Onto A Small Gain",
                "features": {
                    "keywords": [
                        "Swiss",
                        "Stock",
                        "Market",
                        "Small",
                        "Gain"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "market"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-11",
                "original_text": "European Markets Finished Mostly Lower In Choppy Trade",
                "features": {
                    "keywords": [
                        "European",
                        "Markets",
                        "Finished",
                        "Lower",
                        "Choppy",
                        "Trade"
                    ],
                    "sentiment_score": -0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "market"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-01-12",
                "original_text": "How Incyte’s Product Portfolio Is Looking in August",
                "features": {
                    "keywords": [
                        "Incyte",
                        "Product",
                        "Portfolio",
                        "August"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-15",
                "original_text": "Novartis Breast Cancer Drug Trial a Success",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Breast",
                        "Cancer",
                        "Drug",
                        "Trial",
                        "Success"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals",
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-16",
                "original_text": "Novartis: Phase III SOLAR-1 Trial On PI3K Inhibitor BYL719 Met Primary Goal",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Phase",
                        "III",
                        "SOLAR-1",
                        "Trial",
                        "PI3K",
                        "Inhibitor",
                        "BYL719",
                        "Primary",
                        "Goal"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals",
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}